Phase 2 Narcolepsy Trial, Recruiting (NCT07096674)

Phase 2 Narcolepsy Trial, Recruiting NCT07096674 Sponsor: Centessa Pharmaceuticals (UK) Limited Condition: Narcolepsy

Printed from Voxsanity (voxsanity.com.au) — NCT07096674 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Narcolepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with narcolepsy (type 1 or type 2) or a condition called idiopathic hypersomnia (a sleep disorder causing excessive daytime sleepiness), and you previously qualified for and completed the full treatment period in a related earlier study called CRYSTAL-1 (study code ORX750-0201)
You are willing and able to follow the additional rules and requirements of this study

Who may not be able to join:

You have developed a new illness or health condition since the earlier study that the study doctor believes would prevent you from safely continuing in this trial
You are unable to stop taking certain medications that are not allowed in this study, including some medicines used to treat narcolepsy or idiopathic hypersomnia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 617-468-5770

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07096674

Sponsor: Centessa Pharmaceuticals (UK) Limited

Phase: Phase 2

Status: Recruiting

Condition: Narcolepsy

Trial contact: 617-468-5770

More information: https://clinicaltrials.gov/study/NCT07096674

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with narcolepsy (type 1 or type 2) or a condition called idiopathic hypersomnia (a sleep disorder causing excessive daytime sleepiness), and you previously qualified for and completed the full treatment period in a related earlier study called CRYSTAL-1 (study code ORX750-0201)
You are willing and able to follow the additional rules and requirements of this study

Who may not be able to join:

You have developed a new illness or health condition since the earlier study that the study doctor believes would prevent you from safely continuing in this trial
You are unable to stop taking certain medications that are not allowed in this study, including some medicines used to treat narcolepsy or idiopathic hypersomnia

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Centessa Pharmaceuticals (UK) Limited

Registry

ClinicalTrials.gov

Start date

12 August 2025

Est. completion

30 April 2026

Where this trial is recruiting

🇨🇦 Canada 🇮🇹 Italy 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs; Abnormal Laboratory Tests; Abnormal Vital Signs; Abnormal ECG; Suicidal Ideation or Behavior

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov